
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is positioned to be a top competitor in the biopharmaceutical development industry, with a strong pipeline including VK2809 and VK5211, as well as their recently completed IND filing for VK3019. With a favorable mix of potency and safety, VK2809 has the potential to be a best-in-class TRβ. The company has a strong cash runway that should support key value-driving milestones, and their ongoing flexibility to pursue strategic opportunities through partnerships or acquisitions adds to their overall value proposition.
Bears say
Viking Therapeutics is focused on developing therapies for metabolic and endocrine disorders, with a lead drug candidate, VK2735, in both oral and subcutaneous formulations. While the company has promising pipeline assets, there is a risk of commercial failure if Viking is unable to secure sufficient manufacturing agreements and if their oral program for VK2735 is not viable. The company's current financials in terms of revenue and partnerships may not be enough to support the commercialization and development of their drugs.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares